查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1720007

院內感染治療市場，按藥物類型、給藥途徑、感染類型、國家和地區分類：行業分析、市場規模、市場佔有率及 2025 年至 2032 年預測

Hospital Acquired Infections Therapeutic Market, By Drug Type, By Route of Administration, By Infection Type, By Country, and By Region: Industry Analysis, Market Size, Market Share, and Forecast from 2025 to 2032
出版日期: | 出版商: AnalystView Market Insights | 英文 396 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

院內感染治療市場規模預計在 2024 年達到 138.75 億美元，2025 年至 2032 年期間的複合年成長率為 3.70%。

院內感染治療市場-市場動態

醫療保健支出上漲推動市場成長

預計醫療保健成本的上漲將推動醫院感染控制市場的成長。醫療保健支出是指在特定時期內，通常在個人、社區、國家或全球範圍內，用於醫療保健相關服務、產品和活動的總支出。隨著醫療保健支出的增加，醫院和醫療機構正準備分配更多資源用於採用先進的感染預防技術​​，其中包括先進的消毒系統、智慧監控設備等創新解決方案以及其他改善整體感染控制措施的技術。例如，2024 年 5 月，英國政府部門國家統計局報告稱，2022 年至 2023 年期間，醫療保健總支出名義上成長了 5.6%，而 2022 年的成長率為 0.9%。因此，醫療保健支出的增加將推動未來院內感染控制市場的成長。

院內感染治療市場—關鍵洞察

根據我們的研究分析師預測，2025 年至 2032 年間全球市場的複合年成長率將達到約 3.70%。

根據藥品類型細分，抗菌藥物類別收入最高。

根據感染類型細分，2024 年，血液感染細分市場佔據主導地位。

按地區分類，2024 年歐洲的收入最高。

院內感染治療市場-細分分析：

全球離型膜市場分為四大類：藥物類型、給藥途徑、感染類型、地理位置。

根據藥物類型，市場分為四類：抗菌藥物、抗真菌藥物、抗病毒藥物和其他藥物類型。 2024 年，抗菌藥物佔據了 HAI 治療市場的主導地位。這種主導地位是因為細菌是導致絕大多數 HAI 的原因。因此，院內感染有很大一部分是用抗菌藥物治療的。此外，抗菌療法是所有醫院內感染的第一線治療方法。所有感染革蘭氏陽性和革蘭氏陰性病原體的患者都必須接受抗生素治療。應先根據多種耐多藥細菌的危險因子來考慮經驗性抗生素治療。經驗性抗生素療法用於預防腎臟損傷、腎盂腎炎和血液感染等併發症。抗菌治療最短可至7天，最長可至14-21天。

根據感染類型，市場分為五個部分：手術部位感染、泌尿道感染、血液感染、呼吸器相關性肺炎和其他醫院感染。 2024 年，血液感染領域佔據最大的市場佔有率。血流感染，也稱為敗血症或菌血症，是由細菌或其他病原體進入血液引起的嚴重感染。它們是由多種微生物引起的，包括細菌、病毒和真菌，並可能導致嚴重的併發症，如感染性休克、器官衰竭和死亡。血流感染是醫院內發病和死亡的主要原因，尤其是重症病人。

院內感染治療市場—地理洞察

該市場在地理上分佈廣泛，涵蓋歐洲、中東、北美、亞太地區、非洲和拉丁美洲。這些地區根據帶來貿易的國家進一步分類。 2024 年，歐洲將主導 HAI 治療市場，預計這一趨勢將在整個研究期間持續下去。這種優勢歸因於歐洲國家院內感染的高發性，以及該地區越來越多的新型院內感染療法的批准和推出。此外，由於葛蘭素史克公司、羅氏公司、艾爾建公司和拜耳公司等主要公司在歐洲國家的存在，新型醫院內感染治療藥物在歐洲國家的供應增加，預計將支持該地區的成長。

預計預測期內亞太地區的 HAI 治療市場將大幅成長。這一成長是由於印度和中國等新興經濟體中慢性病盛行率上升，導致住院人數增加。例如，Globocan 報告稱，2018 年中國診斷出約 4,285,033 例新癌症病例。因此，預計院內感染和住院率的上升將推動對院內感染治療藥物的需求並支持區域成長。

院內感染治療市場-競爭格局：

默克公司、雅培、羅氏公司、艾伯維和艾爾建等主要製藥公司在院內感染 (HAI) 治療市場展開競爭，專注於開發創新抗生素和抗菌療法。此外，新興生物技術公司正在研究單株抗體和噬菌體療法等利基治療方法。作為改善藥物開發和應對院內感染日益增多的一種方式，成熟公司和新創公司之間的合作正變得越來越普遍。隨著抗生素抗藥性的蔓延，競爭日益激烈，凸顯了醫療環境中對有效治療方案和更好的病患治療效果的需求。例如，2024 年 4 月，FDA 批准了巴塞利亞製藥國際有限公司 (Basilea Pharmaceutica International Ltd.) 的新型血液感染治療藥物 Zevtera，標誌著該公司達到了一個重要的里程碑。此次批准對於 Basilea 來說是一項重大策略舉措，鞏固了其在 HAI 治療領域的市場領先地位。 Zevtera 的核准將拓寬嚴重感染的治療選擇，改善患者的治療效果，並透過創新解決方案增強 Basilea 的市場地位。

最新動態：

2023 年 10 月，Spartan Medical Inc. 發起了一項新活動，以提高全美對手術部位感染 (SSI) 及其後果的認知。該策略旨在教育醫療保健專業人員和患者了解 SSI 的風險和預防的重要性，從而增加對先進感染控制措施和治療解決方案的需求。這項活動強調了 Spartan Medical 致力於解決關鍵醫療保健挑戰的決心，從而加強了該公司在感染控制市場的地位。

2022 年 4 月，輝瑞簽署最終協議，收購 ReViral，這是一家專注於開發呼吸道合胞病毒 (RSV) 抗病毒療法的臨床階段生物製藥公司。此次收購將有助於輝瑞擴大在抗病毒治療領域的影響力，並支持其開發呼吸道合胞病毒和其他呼吸道感染的新療法。

2021 年 12 月，默克（在美國和加拿大以外地區稱為 MSD）和 Ridgeback Biotherapeutics 宣布，他們的抗病毒藥物莫努皮拉韋已獲得美國食品藥物管理局 (FDA) 的緊急使用授權 (EUA)，用於治療 COVID-19。這是全球對抗新冠肺炎疫情努力向前邁出的重要一步，它繼承了默克公司開發應對重大健康威脅和改善患者預後的創新藥物的歷史。

目錄

第1章：院內感染治療市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 院內獲得性感染治療市場（依藥物類型）
    • 院內獲得性感染治療市場片段（依給藥途徑）
    • 院內獲得性感染治療市場片段（依感染類型）
    • 院內感染治療市場（按國家/地區）
    • 院內感染治療市場（按地區）
  • 競爭洞察

第3章：醫院內獲得性感染治療關鍵市場趨勢

  • 院內感染治療市場促進因素
    • 市場促進因素的影響分析
  • 醫院內感染治療市場限制
    • 市場限制的影響分析
  • 院內感染治療市場機遇
  • 院內感染治療市場未來趨勢

第4章：醫院內獲得性感染治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：院內感染治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • 新冠疫情後影響分析
    • 表現最佳的市場區隔
    • 邊際成長細分市場
    • 最鬆散的細分市場
    • 邊際損失市場區隔

第6章：醫院內獲得性感染治療市場格局

  • 2024年院內感染治療市佔率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：院內感染治療市場－依藥物類型

  • 概述
    • 按藥物類型分類的細分市場佔有率分析
    • 抗菌藥物
    • 抗真菌藥物
    • 抗病毒藥物
    • 其他藥物類型

第 8 章：院內感染治療市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 靜脈注射（IV）
    • 外用
    • 口服
    • 吸入

第9章：院內感染治療市場－依感染類型

  • 概述
    • 按感染類型分類的細分佔有率分析
    • 手術部位感染
    • 泌尿道感染
    • 血流感染
    • 呼吸器相關性肺炎
    • 其他醫院感染

第 10 章：院內感染治療市場 - 按地區

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美醫院內感染治療主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（依藥品類型）
    • 北美市場規模及預測（按給藥途徑）
    • 北美市場規模及預測（按感染類型）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲院內感染治療主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（依藥品類型）
    • 歐洲市場規模及預測（依管理途徑）
    • 歐洲市場規模及預測（按感染類型）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區醫院內感染治療主要製造商
    • 亞太市場規模及預測（按國家/地區）
    • 亞太市場規模及預測（依藥品類型）
    • 亞太地區市場規模及預測（依給藥途徑）
    • 亞太市場規模及預測（依感染類型）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲醫院內感染治療主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依藥品類型）
    • 拉丁美洲市場規模及預測（按給藥途徑）
    • 拉丁美洲市場規模及預測（按感染類型）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲院內感染治療主要製造商
    • 中東和非洲市場規模及預測（按國家/地區）
    • 中東和非洲市場規模及預測（依藥品類型）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按感染類型）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 11 章：關鍵供應商分析-院內感染治療產業

  • 競爭儀錶板
  • 公司簡介
    • Merck & Co.
    • Abbott
    • F. Hoffmann-La Roche
    • AbbVie
    • Allergan Plc
    • Eugia Pharma
    • Bayer
    • DAIICHI SANKYO COMPANY
    • Glenmark Pharmaceuticals
    • GSK
    • Hikma Pharmaceuticals
    • Melinta Therapeutics
    • Pfizer
    • Sanofi
    • Viatris
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5006

REPORT HIGHLIGHT

Hospital Acquired Infections Therapeutic Market size was evaluated at USD 13,875 million in 2024, rising at a CAGR of 3.70% between 2025 and 2032.

Hospital-acquired infections are infections that develop during hospitalisation that were not present before admission. Hospital-acquired infection control refers to the prevention and control of hospital-acquired infections through various cleaning, sterilisation, and disinfection techniques. These infections can be caused by cross-contamination of equipment surfaces, patient skin, and healthcare staff. Infection control in hospitals is used to reduce or eliminate disease transmission.

Hospital Acquired Infections Therapeutic Market- Market Dynamics

Rising healthcare expenditures drive market Growth

Rising healthcare costs are expected to drive the growth of the hospital-acquired infection control market. Healthcare expenditures are the total amount spent on healthcare-related services, products, and activities over a given period, usually on an individual, community, national, or global scale. As healthcare spending rises, hospitals and healthcare facilities are preparing to allocate more resources to the adoption of advanced infection prevention technologies, which include innovative solutions such as advanced disinfection systems, smart monitoring devices, and other technologies that improve overall infection control measures. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared to 0.9% in 2022. As a result, rising healthcare expenditure will drive future growth in the hospital-acquired infection control market.

Hospital Acquired Infections Therapeutic Market- Key Insights

According to our research analyst, the global market is expected to increase at a CAGR of approximately 3.70% between 2025 and 2032.

Based on Drug Type segmentation, the antibacterial drugs category had the highest income.

Based on Infection Type segmentation, In 2024, the bloodstream infections segment dominated the market.

According to region, Europe had the most revenue in 2024.

Hospital Acquired Infections Therapeutic Market- Segmentation Analysis:

The global release liner market is divided into four groups: Drug Type, Route of Administration, Infection Type, and geography.

The market is divided into four categories based on drug type: antibacterial drugs, antifungal drugs, antiviral drugs, and other drug types. Antibacterial drugs dominated the HAI therapeutics market in 2024. This dominance is because bacteria cause the vast majority of HAIs. As a result, a large proportion of HAIs are treated with antibacterial drugs. Furthermore, antibacterial therapy is the first line of treatment for all hospital-acquired infections. All patients infected with gram-positive and gram-negative pathogens must be treated with antibiotics. Empiric antibiotic therapy should be considered first based on a variety of risk factors for multidrug-resistant bacteria. Empiric antibiotic therapy is used to prevent complications like kidney damage, pyelonephritis, and bloodstream infections. Antibacterial therapy can be as short as 7 days or as long as 14-21 days.

Based on the type of infection, the market is divided into five segments: surgical site infections, urinary tract infections, bloodstream infections, ventilator-associated pneumonia, and other hospital infections. In 2024, the bloodstream infections segment held the largest market share. Bloodstream infections, also referred to as sepsis or bacteremia, are serious infections caused by bacteria or other pathogens entering the bloodstream. They are caused by a variety of microorganisms, including bacteria, viruses, and fungi, and can lead to serious complications like septic shock, organ failure, and death. Bloodstream infections are a major cause of morbidity and mortality in hospital settings, particularly among critically ill patients.

Hospital Acquired Infections Therapeutic Market- Geographical Insights

This market is geographically diversified across Europe, the Middle East, North America, Asia Pacific, and Africa, Latin America. The regions are further divided by the nations that bring commerce. In 2024, Europe dominated the market for HAI therapeutics, and this trend is expected to continue throughout the study period. This dominance is attributed to the high prevalence of HAIs in European countries, as well as the region's increasing approvals and launches of novel HAI therapeutics. Furthermore, the increased availability of novel hospital-acquired infection therapeutics in European countries due to the local presence of major players such as GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Allergan Plc, and Bayer AG is expected to support regional growth.

The HAIs therapeutics market in Asia Pacific is expected to grow significantly during the forecast period. This increase is attributed to the rising prevalence of chronic diseases in emerging economies like India and China, which has resulted in more hospitalisations. For example, Globocan reported that approximately 4,285,033 new cancer cases were diagnosed in China in 2018. Thus, the rising rate of HAIs and hospitalisations is expected to drive demand for HAI therapeutic drugs and support regional growth.

Hospital Acquired Infections Therapeutic Market- Competitive Landscape:

Major pharmaceutical companies such as Merck & Co., Abbott, F. Hoffmann-La Roche, AbbVie, and Allergan Plc compete in the Hospital Acquired Infections (HAIs) Therapeutic Market, with a focus on developing innovative antibiotics and antimicrobial therapies. Additionally, emerging biotech firms are investigating niche treatments such as monoclonal antibodies and bacteriophage therapy. Collaborations between established companies and startups are becoming more common as a way to improve drug development and address the rising prevalence of HAIs. As antibiotic resistance spreads, competition heats up, highlighting the need for effective treatment options and better patient outcomes in healthcare settings. For instance, in April 2024, Basilea Pharmaceutica International Ltd. reached a significant milestone when the FDA approved its new bloodstream infection treatment, Zevtera. This approval is a significant strategic move for Basilea, cementing its position as a market leader in HAI therapies. Zevtera's approval will broaden treatment options for severe infections, improving patient outcomes and strengthening Basilea's market presence through innovative solutions.

Recent Developments:

In October 2023, Spartan Medical Inc. launched a new campaign to increase awareness of surgical site infections (SSIs) and their consequences throughout the United States. This strategy aims to educate healthcare professionals and patients about the risks of SSIs and the importance of prevention, resulting in increased demand for advanced infection control measures and therapeutic solutions. The campaign strengthens Spartan Medical's position in the infection control market by emphasising the company's dedication to addressing critical healthcare challenges.

In April 2022, Pfizer signed a definitive agreement to acquire ReViral, a clinical-stage biopharmaceutical company focused on developing antiviral therapies for respiratory syncytial virus (RSV). The acquisition will help Pfizer expand its presence in the antiviral therapeutics field and support its efforts to develop new treatments for RSV and other respiratory infections.

In December 2021, Merck, also known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that their antiviral drug molnupiravir has been granted Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of COVID-19. This is a significant step forward in the global effort to combat the COVID-19 pandemic, building on Merck's history of developing innovative drugs that address major health threats and improve patient outcomes.

SCOPE OF THE REPORT

This report's scope includes the following important market segments:

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Merck & Co.
  • Abbott
  • F. Hoffmann-La Roche
  • AbbVie
  • Allergan Plc
  • Eugia Pharma
  • Bayer
  • DAIICHI SANKYO COMPANY
  • Glenmark Pharmaceuticals
  • GSK
  • Hikma Pharmaceuticals
  • Melinta Therapeutics
  • Pfizer
  • Sanofi
  • Viatris
  • Others

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antibacterial drugs
  • Antifungal drugs
  • Antiviral drugs
  • Other drug types

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous (IV)
  • Topical
  • Oral
  • Inhalation

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2019 - 2032

  • Surgical site infections
  • Urinary tract infections
  • Bloodstream infections
  • Ventilator-associated pneumonia
  • Other hospital infections

GLOBAL HOSPITAL ACQUIRED INFECTIONS THERAPEUTIC MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Hospital Acquired Infections Therapeutic Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Hospital Acquired Infections Therapeutic Market Snippet by Drug Type
    • 2.1.2. Hospital Acquired Infections Therapeutic Market Snippet by Route of Administration
    • 2.1.3. Hospital Acquired Infections Therapeutic Market Snippet by Infection Type
    • 2.1.4. Hospital Acquired Infections Therapeutic Market Snippet by Country
    • 2.1.5. Hospital Acquired Infections Therapeutic Market Snippet by Region
  • 2.2. Competitive Insights

3. Hospital Acquired Infections Therapeutic Key Market Trends

  • 3.1. Hospital Acquired Infections Therapeutic Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Hospital Acquired Infections Therapeutic Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Hospital Acquired Infections Therapeutic Market Opportunities
  • 3.4. Hospital Acquired Infections Therapeutic Market Future Trends

4. Hospital Acquired Infections Therapeutic Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Hospital Acquired Infections Therapeutic Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Hospital Acquired Infections Therapeutic Market Landscape

  • 6.1. Hospital Acquired Infections Therapeutic Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Hospital Acquired Infections Therapeutic Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. Antibacterial drugs
    • 7.1.3. Antifungal drugs
    • 7.1.4. Antiviral drugs
    • 7.1.5. Other drug types

8. Hospital Acquired Infections Therapeutic Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Intravenous (IV)
    • 8.1.3. Topical
    • 8.1.4. Oral
    • 8.1.5. Inhalation

9. Hospital Acquired Infections Therapeutic Market - By Infection Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Infection Type, 2024 & 2032 (%)
    • 9.1.2. Surgical site infections
    • 9.1.3. Urinary tract infections
    • 9.1.4. Bloodstream infections
    • 9.1.5. Ventilator-associated pneumonia
    • 9.1.6. Other hospital infections

10. Hospital Acquired Infections Therapeutic Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Hospital Acquired Infections Therapeutic Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Hospital Acquired Infections Therapeutic Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Hospital Acquired Infections Therapeutic Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co.
    • 11.2.2. Abbott
    • 11.2.3. F. Hoffmann-La Roche
    • 11.2.4. AbbVie
    • 11.2.5. Allergan Plc
    • 11.2.6. Eugia Pharma
    • 11.2.7. Bayer
    • 11.2.8. DAIICHI SANKYO COMPANY
    • 11.2.9. Glenmark Pharmaceuticals
    • 11.2.10. GSK
    • 11.2.11. Hikma Pharmaceuticals
    • 11.2.12. Melinta Therapeutics
    • 11.2.13. Pfizer
    • 11.2.14. Sanofi
    • 11.2.15. Viatris
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us